Mini-review explores oxidized mannan-conjugated MOG peptide for multiple sclerosis immunotherapy
Photo by National Institute of Allergy and Infectious Diseases / Unsplash
Key Takeaway
Interpret these preclinical findings cautiously; OM-MOG35-55 shows potential tolerogenic effects but requires clinical validation.
This mini-review synthesizes preclinical evidence on the use of oxidized mannan-conjugated myelin oligodendrocyte glycoprotein peptide (OM-MOG35-55) as a potential immunotherapy for multiple sclerosis (MS). The review covers experimental models and human immune cells, focusing on the compound's ability to modulate immune responses. Key findings include enhanced dendritic cell-mediated antigen presentation, expansion of CD4+PD-1+ and CD4+CD25+Foxp3+ T-cell populations, and production of regulatory cytokines such as IL-10 and TGF-β1. These effects suggest a tolerogenic mechanism that could suppress autoimmune activity in MS.
The authors acknowledge several limitations. The precise mechanisms underlying OM-MOG-mediated immune modulation are not fully defined. Additionally, the antigenic heterogeneity of MS and the limited predictive value of experimental autoimmune encephalomyelitis (EAE) models restrict the generalizability of these findings. The review does not report sample sizes, comparator groups, or primary outcomes, reflecting its early-stage, narrative nature.
Safety data are not reported, and no clinical trials are discussed. The review proposes a roadmap toward clinical validation but emphasizes that these are preclinical findings. Clinicians should recognize that this work is exploratory and does not yet support clinical application. Further research is needed to clarify mechanisms and assess safety and efficacy in humans.
More on Multiple Sclerosis
Aerobic and strength training reduce fatigue in multiple sclerosis patients
Aerobic or strength training eases MS fatigue, trial finds
This randomized effectiveness trial in 62 persons with multiple sclerosis and fatigue found that 8 weeks of aerobic training, strength train…
A small trial finds that aerobic and strength training each reduce fatigue in MS, with no clear winner among exercise types.
Laughter yoga reduced fatigue in people with multiple sclerosis in a randomized controlled trial
Laughter Yoga Cuts Fatigue And Improves Sleep For Multiple Sclerosis Patients
This randomized controlled trial enrolled 42 people with multiple sclerosis. Participants in the intervention group received 12 sessions of …
People with multiple sclerosis who practiced laughter yoga reported less tiredness and better sleep after just twelve sessions.
Exercise training improves cognition and fatigue in older adults with multiple sclerosis
Exercise boosts brain and cuts fatigue in older adults with MS
This Phase-Ib randomized controlled trial in 51 older adults with multiple sclerosis found that 16 weeks of home-based aerobic and resistanc…
A 16-week home exercise program improved thinking speed, executive function, fatigue, and quality of life in older adults with multiple scle…
Meta-analysis finds PLISSIT counseling improves sexual life in women with MS
Counseling helps sexual life for women with Multiple Sclerosis
This systematic review and meta-analysis of 232 women with multiple sclerosis found that counseling interventions based on the PLISSIT model…
A new review found counseling based on the PLISSIT model had a high and positive effect on the sexual lives of women with Multiple Sclerosis…
View Original Abstract ↓
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by autoreactive T-cell responses against myelin antigens. Current disease-modifying therapies (DMTs) broadly suppress immune activity but do not restore antigen-specific immune tolerance and may cause significant adverse effects. Antigen-specific immunotherapies offer a rational alternative aimed at selectively re-educating the immune system without compromising protective immunity. Structural determinants of myelin antigens, including arginine-dependent conformational stability and post-translational modifications such as citrullination, critically influence their immunogenic and tolerogenic properties. Recent advances highlight the potential of oxidized mannan-conjugated myelin oligodendrocyte glycoprotein peptide (OM-MOG35-55) to modulate antigen-specific immune responses in experimental models and human immune cells. Studies suggest that OM-MOG35-55 can influence dendritic cell (DC)-mediated antigen presentation and favor the expansion of CD4+PD-1+ and CD4+CD25+Foxp3+ T-cell populations and the production of regulatory cytokines such as IL-10 and TGF-β1. When combined with vitamin D3 conditioning of DCs, the immunomodulatory potential of OM-MOG35-55 appears enhanced. Nevertheless, the precise mechanisms underlying OM-MOG-mediated immune modulation are not fully defined, and the antigenic heterogeneity of MS and the limited predictive value of EAE models highlight the need for cautious interpretation of preclinical findings. This mini-review integrates structural, immunological, and translational evidence supporting OM-MOG35-55 as a promising platform for antigen-specific immunotherapeutic design and proposes a roadmap toward clinical validation of this immunotherapeutic strategy for MS.
Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma.
New Asthma Drug Cuts Attacks Without Recent Crisis
Related in Allergy & Immunology
Emergency-use spacers improve salbutamol delivery in asthmatics compared to pMDI alone
Spacers boost asthma drug delivery over inhaler alone
This randomized trial in 108 asthmatics compared emergency-use spacers with pMDI alone. Spacers significantly increased urinary salbutamol a…
Using a spacer with your asthma inhaler delivers more medication to the lungs, a new trial finds. Some spacers work better than others.
Repeated counseling with pMDI devices reduced inhalation errors in adult asthma patients compared to pMDI alone.
Spacer Devices Fix Asthma Faster Than Inhalers Alone
This prospective randomized clinical trial enrolled 300 adult asthma patients to compare repeated counseling on inhalation technique using p…
Using a spacer with an inhaler reduces mistakes and improves lung health much faster than using the inhaler alone for adults with asthma
Montelukast vs Tiotropium Added to ICS in Children With Asthma
Asthma Treatment Comparison Shows Mixed Results for Kids
This randomized controlled trial in 152 children aged 6 to 14 years with partly controlled or uncontrolled asthma found no significant diffe…
A small trial found no clear difference between two asthma medicines for children, though one caused rare side effects.
Nurse-led rehabilitation consultation improves asthma control in primary care
A Simple 4-Week Plan Helps Asthma Control
This randomized controlled trial in 124 adults with asthma found that a nurse-led structured rehabilitation consultation significantly impro…
A simple four-week nurse program helps adults manage asthma better than usual care alone.
From Other Specialties
Observational study assesses MiniDock MTB diagnostic accuracy against Xpert in Indonesian TB patients
New TB test shows promise in Indonesia trial
This observational study evaluated the diagnostic accuracy of MiniDock MTB on sputum swabs compared to Xpert MTB/RIF Ultra and liquid cultur…
A new TB test called MiniDock MTB accurately detected TB in adults, but sensitivity dropped in children and low-burden cases.
Phase 1 study traces ainuovirine metabolism and excretion in healthy men
A single dose of oral ainuovirine clears the body within two days in healthy men
This phase 1 open-label study in 6 healthy men examined the pharmacokinetics and mass balance of a single dose of radiolabelled ainuovirine.…
A single dose of oral ainuovirine clears the body within two days in healthy men, with most of the drug leaving unchanged through urine and …
Nirmatrelvir/Ritonavir in Breast Milk: Low Infant Exposure in Lactating Women
Paxlovid levels low in breast milk, early study finds
This Phase 1 open-label study in 8 healthy lactating women found that nirmatrelvir/ritonavir concentrations in breast milk were consistently…
A small study finds that nirmatrelvir/ritonavir (Paxlovid) passes into breast milk at low levels, suggesting minimal infant exposure.
Islatravir and lenacapavir fixed-dose combination shows similar bioavailability to single agents in healthy volunteers
New HIV pill works with or without food in early safety tests
This open-label phase 1 study enrolled 93 people without HIV to assess the oral relative bioavailability and safety of a fixed-dose combinat…
A new HIV pill containing islatravir and lenacapavir showed similar drug levels whether taken with food or on an empty stomach, supporting f…